Three Tickers Nobody's Talking About That Are Actually Doing Something: $ELAN, $RARE, and $FLEX

While the financial internet melts down over oil futures investigations and Gundlach's 2007 comparisons, a few genuinely interesting companies are doing the boring work of, you know, growing. Let's talk about three of them.

$ELAN (Elanco Animal Health) just posted its best quarter since spinning out of Eli Lilly in 2018 — 10% farm-side growth, high single-digit pet-side growth, and it's actively stealing market share from Zoetis. The omni-channel play from dollar stores to Chewy is underappreciated. Catalyst: multi-year mid-single-digit top-line growth targets with margin expansion — and most people still think of this as a dusty Lilly leftover. It's not.

$RARE (Ultragenyx Pharmaceutical) is running a literal bootcamp for rare disease families — over 230 graduates since 2017 — building a pipeline moat that's as much community loyalty as it is science. With 95%+ of rare diseases lacking approved therapies, the addressable market is absurd and the competition is thin. And $FLEX is spinning off its Cloud and Power Infrastructure unit, which grew 38% last year and is guiding 65–75% growth this year. A standalone AI infrastructure and grid modernization company hiding inside a contract manufacturer is the kind of setup that makes you want to flip over the couch cushions looking for more.

Three different sectors, three different stories — all with the same underlying plot: everyone's looking at the shiny stuff while the real money quietly compounds in the corner.